Evidence map›Paper›PMID 41958601›Full record

ArticleJournal of human reproductive sciences

Efficacy of an Extended 10-day Letrozole Regimen Compared to the 5-day Regimen in Enhancing Ovulation in Infertile Women with Polycystic Ovary Syndrome: A Randomised Controlled Trial.

Bhavneet Kaur, Archana Kumari, Reeta Mahey, Maroof Ahamad Khan, Aarthi K Jayraj, Neena Malhotra

Abstract read
In one paragraph

Article in Journal of human reproductive sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bhavneet KaurDepartment of Obstetrics and Gynaecology and AIIMS, New Delhi, India.
Archana KumariDepartment of Obstetrics and Gynaecology and AIIMS, New Delhi, India.
Reeta MaheyDepartment of Obstetrics and Gynaecology and AIIMS, New Delhi, India.
Maroof Ahamad KhanDepartment of Biostatistics, AIIMS, New Delhi, India.
Aarthi K JayrajDepartment of Obstetrics and Gynaecology and AIIMS, New Delhi, India.
Neena MalhotraDepartment of Obstetrics and Gynaecology and AIIMS, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polycystic ovary syndrome (PCOS) is a leading cause of anovulatory infertility. Letrozole is the first-line agent for ovulation induction; however, response to the standard 5-day regimen may be suboptimal in some women. Aim: The aim is to compare the efficacy and safety of an extended 10-day letrozole regimen with the conventional 5-day regimen for ovulation induction in infertile women with PCOS. Settings and Design: Prospective, open-label, parallel-group randomised controlled trial conducted at a tertiary care centre in North India. Materials and Methods: Eighty infertile women with PCOS (Rotterdam criteria, 2003) were randomised to receive either letrozole 2.5 mg daily for 10 days or 5 days. Up to three ovulation induction cycles were allowed. Follicular monitoring was performed using transvaginal ultrasonography. Ovulation was triggered with human chorionic gonadotropin, followed by timed intercourse. Statistical Analysis Used: Continuous variables were analysed using the Results: The 10-day regimen showed a significantly higher follicular response in the first cycle compared to the 5-day regimen (85.0% vs. 52.5%, Conclusion: The extended 10-day letrozole regimen significantly improves follicular response without increasing adverse outcomes and may improve cycle efficiency in women with PCOS.

Indexed as

Infertilityletrozoleovulation inductionpolycystic ovary syndromerandomised controlled trial

Identifiers

PMID41958601
PMCPMC13061141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.